Trial
NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Lymphoma, T-Cell, Cutaneous
Intervention
Pacritinib
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-22